CWM
ABBV icon

Cadence Wealth Management’s AbbVie ABBV Stock Holding History

Cadence Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237K Buy
+943
New +$203K 0.11% 56
2025
Q4 		– Sell
-867
Closed -$201K – 58
2025
Q3 		$201K Buy
+867
New +$177K 0.11% 56

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cadence Wealth Management's ABBV Position: Q2 2026 in Review

Cadence Wealth Management opened a new position in AbbVie (ABBV) in Q2 2026: 943 shares worth $237K. The stake represents 0.11% of the portfolio and ranks #56 among its holdings. This is a return to the name: Cadence Wealth Management previously reported a position in ABBV as recently as Q3 2025.

Cadence Wealth Management first reported a position in ABBV in Q3 2025 and has held it in 2 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Cadence Wealth Management held 943 shares of AbbVie worth $237K as of Q2 2026.
  • AbbVie was a new Cadence Wealth Management position in Q2 2026.
  • AbbVie made up 0.11% of Cadence Wealth Management's portfolio in Q2 2026, its #56 holding.
  • Cadence Wealth Management first reported a position in AbbVie in Q3 2025 and has held it in 2 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cadence Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.